Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years

NCT06715891 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

374

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Respiratory Viral Infection

Interventions

DRUG: Raphamin
DRUG: Placebo

Sponsor

Materia Medica Holding